|
gptkbp:instance_of
|
gptkb:pharmaceuticals
gptkb:Company
|
|
gptkbp:acquired_by
|
gptkb:Bayer_AG
|
|
gptkbp:acquisition
|
gptkb:Schering-Plough_Corporation
gptkb:Bayer_AG
increased resources for R& D
|
|
gptkbp:ceo
|
gptkb:Michael_Houghton
|
|
gptkbp:dissolved
|
gptkb:2006
|
|
gptkbp:employees
|
approximately 20,000
approximately 25,000 (2006)
|
|
gptkbp:founded
|
1820
1821
|
|
gptkbp:founder
|
gptkb:Hermann_Schering
|
|
gptkbp:headquarters
|
gptkb:Berlin,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Schering AG
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:key_people
|
gptkb:Hermann_Schering
gptkb:Klaus_P._W._Schering
|
|
gptkbp:location
|
gptkb:Germany
|
|
gptkbp:market_position
|
global
|
|
gptkbp:operates_in
|
healthcare
|
|
gptkbp:parent_company
|
gptkb:Bayer_AG
|
|
gptkbp:partnership
|
gptkb:Sanofi-Aventis
gptkb:Glenmark_Pharmaceuticals
gptkb:pharmaceuticals
gptkb:Johnson_&_Johnson
gptkb:Aurobindo_Pharma
gptkb:Takeda_Pharmaceutical_Company
gptkb:Cipla
gptkb:Merck_KGa_A
gptkb:Astra_Zeneca
gptkb:Alvogen
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Pfizer_Inc.
gptkb:Biocon_Limited
gptkb:Wockhardt
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Intas_Pharmaceuticals
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:Sandoz
gptkb:Hikma_Pharmaceuticals
gptkb:Astellas_Pharma
gptkb:Eli_Lilly_and_Company
gptkb:Lupin_Pharmaceuticals
gptkb:Sun_Pharmaceutical_Industries
gptkb:Abb_Vie
gptkb:Glaxo_Smith_Kline
gptkb:Mylan_N._V.
gptkb:Novartis
gptkb:Zydus_Cadila
gptkb:Dr._Reddy's_Laboratories
gptkb:Cadila_Healthcare
gptkb:Torrent_Pharmaceuticals
Hetero Drugs
|
|
gptkbp:product_line
|
gptkb:cosmetics
gptkb:medical_devices
antibiotics
antivirals
diagnostic tests
nutritional supplements
vaccines
biologics
hormonal therapies
antidepressants
antipsychotics
anti-inflammatory drugs
cancer treatments
biosimilars
fertility treatments
anesthetics
gene therapies
herbal medicines
immunology drugs
cell therapies
cardiovascular drugs
respiratory drugs
homeopathic remedies
diagnostic imaging agents
orphan drugs
contraceptives
dermatological products
geriatric medications
pediatric medications
gastrointestinal drugs
pain management drugs
neurology drugs
veterinary medicines
OTC medications
rare disease treatments
compounding medications
hormone replacement therapies
metabolic disorder drugs
|
|
gptkbp:products
|
gptkb:pharmaceuticals
gptkb:Betaferon
gptkb:Clarityn
hormonal therapies
oncology drugs
contraceptives
dermatology products
|
|
gptkbp:research_focus
|
gptkb:biotechnology
clinical trials
drug development
|
|
gptkbp:revenue
|
approximately 5 billion euros
€4.5 billion (2006)
|
|
gptkbp:specialization
|
gptkb:biotechnology
cardiology
oncology
dermatology
therapeutics
radiology
diagnostics
gynecology
|
|
gptkbp:specializes_in
|
gptkb:pharmaceuticals
|
|
gptkbp:stock_exchange
|
gptkb:Frankfurt_Stock_Exchange
|
|
gptkbp:subsidiaries
|
gptkb:Schering-Plough
|
|
gptkbp:subsidiary
|
gptkb:Schering-Plough_Corporation
gptkb:Schering-Plough
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.schering.com
|
|
gptkbp:bfsParent
|
gptkb:Bayer_AG
gptkb:Bayer
|
|
gptkbp:bfsLayer
|
5
|